Patient Access Insights

Access to Orphan Medicines

In this webinar, our panel of experts shine a light on the challenges of appraising medicines for rare diseases and consider solutions and policies for the future.
Request this webinar

Access to Orphan Medicines

Originally broadcast: Tuesday 15th September 2020 at 12:30 – 14:00 BST

Duration: 90 minutes. Available to watch on demand

Learning objectives:

  •  The latest insights and information for accelerating patient access

  •  Understand the challenges of appraising medicines for rare diseases

  •  Develop solutions and policies for the future

  •  Examine the potential for the NICE methods review and proposed Innovative Medicines Fund


Who would benefit from registering to attend this webinar:

This webinar should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.

The job functions that will benefit most include:

• Heads of Market Access

• Managing Directors

• Country Managers

• Chief Executives

• Health Economists

• Medical Directors

• Commercial Directors

• Policy Officers/Executives

• Marketing Directors

• Policy Advisors



Speakers

Speaker%20picture%20 %20Kate%20Learoyd

Kate Learoyd, Campaign Manager, NSPKU – National Society for Phenylketonuria

A solicitor by profession, Kate has wide experience of litigation and regulatory issues. She is currently working at patient charity NSPKU to improve access to drug treatments for people with the rare metabolic condition phenylketonuria.

Speaker%20picture%20 %20Lindsay%20Weaver

Lindsay Weaver, CEO, Metabolic Support UK

Lindsay has championed and led patient groups throughout her career. Starting with St Johns Ambulance, Cheshire Young Carers, she has latterly held Chief Executive Officer positions at the Young Carers Network and Children Living with Inherited Metabolic Disorders.

Speaker%20picture%20 %20Charlie%20Galvin

Charlie Galvin, Board Member, Association of British Pharmaceutical Industry and General Manager, UK and Ireland, Amicus

Charlie has held a number of senior commercial, market access and business development roles at Global pharmaceutical companies including Pfizer, Amgen and currently is the General Manager, UK and Ireland at Amicus.

Terms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2020. MAP BioPharma Limited. All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

+44 (0) 1480 832360

 enquiries@mapbiopharma.com

MAP BioPharma Limited is a registered company in England and Wales. Company Registration Number 08209281

VAT Group Registration Number GB 292 8576 52